10.06.2013 07:35 Uhr, Quelle: Wallstreet online

Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis

Novartis International AG / Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible …

Weiterlesen bei Wallstreet online